TALS News and Press, Talaris Therapeutics Inc. From 05/12/22

Multiple presentations pending at upcoming American Transplant Congress (ATC), as well as concurrent update on ongoing Phase 3 (FREEDOM-1) clinical trial in living donor kidney transplant (LDKT) patients Presented data on COVID-19 outcomes among kidney transplant patients treate...

D ata to be presented include real-world evidence analysis of health outcomes among Phase 2 patients compared to matched controls Updated data on Phase 2 study follow-up, COVID-19 patient outcomes also planned for ATC BOSTON and LOUISVILLE, Ky., May 02, 2022 ...

Talaris Therapeutics (NASDAQ:TALS) presented new data on COVID-19 outcomes among living donor kidney transplant (LDKT) patients treated in the company’s phase 2 trial of investigational cell therapy product FCR001. Data presented at the 2022 Cutting Edge of Transplantation meeting. Res...

Low rate of COVID-19 infection observed in vaccinated, durably chimeric patients off immunosuppression No evidence of acute kidney injury or impaired renal function in FCR001-treated patients with COVID-19 infection No patients lost chimerism as a result of COVID...

BOSTON and LOUISVILLE, Ky., March 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune disorders, toda...

Halvorsen's 13F portfolio value decreased from $36.04B to $34.49B this quarter. The number of positions increased from 96 to 107. Viking Global added Twilio, Workday, and Aon plc while dropping Fidelity National Information Services and Snowflake. The top three positions are Ginkg...

Talaris Therapeutics press release (NASDAQ:TALS): FY GAAP EPS of -$1.64. FY Cash and cash equivalents of market securities $243.9m For further details see: Talaris Therapeutics GAAP EPS of -$1.64

Phase 3 (FREEDOM-1) clinical trial in living donor kidney transplant (LDKT) patients continues; additional data update expected mid-year 2022 Two Phase 2 (FREEDOM-2 and FREEDOM-3) clinical trials of FCR001 initiated in delayed tolerance and scleroderma Robust $244 m...

BOSTON and LOUISVILLE, Ky., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disord...

BOSTON and LOUISVILLE, Ky., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disord...